Immedica UK Limited

Immedica UK Limited

Immedica UK Limited, formerly Diurnal Limited, is the British operating company behind Diurnal's endocrine medicines business. Incorporated in 2004 and historically based in Cardiff, it developed hydrocortisone treatments including Alkindi and Efmody for adrenal disorders. Neurocrine acquired the business in 2022, and Immedica acquired the group in January 2026; the operating company took its current legal name in February 2026.

Key facts

Also Known AsNeurocrine UK Limited
Revenue Typerevenue
Legal NameImmedica UK Limited
Company Operating StatusAcquired
Full AddressCardiff Medicentre, Heath Park, Cardiff, Wales CF14 4UJ, GB
Wellfound IDdiurnal